NCT04685915 2025-05-22Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLLDana-Farber Cancer InstitutePhase 2 Withdrawn
NCT04155840 2022-04-11Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaUniversity of WashingtonPhase 2 Terminated1 enrolled 6 charts